Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Elixinol WellnessASX:EXL Debt-to-Equity is 0.50 as of Dec. 2025, which is 194% above its 10-year median of 0.17. The stock has 7 warning signs investors should review. Among 813 Drug Manufacturers companies, Elixinol Wellness ranks worse than 69.5% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Elixinol Wellness's Debt-to-Equity or its related term are showing as below:
ASX:EXL'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.17 Max: 0.5
Current: 0.5
During the past 8 years, the highest Debt-to-Equity Ratio of Elixinol Wellness was 0.50. The lowest was 0.00. And the median was 0.17.
ASX:EXL's Debt-to-Equity is ranked worse than 69.5% of 813
companies
in the Drug Manufacturers industry
Industry Median: 0.27
vs ASX:EXL: 0.50
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Elixinol Wellness Debt-to-Equity Related Terms
Elixinol Wellness Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Elixinol Wellness's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:EXL vs ZTS, UTHR, VTRS: Debt-to-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Elixinol Wellness's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elixinol Wellness Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Elixinol Wellness's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Elixinol Wellness's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Elixinol Wellness (ASX:EXL) has a Debt-to-Equity of 0.50 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Elixinol Wellness and its competitors. This is 194% above median its historical median of 0.17. According to the industry distribution chart, Elixinol Wellness ranks #565 out of 813 companies in the Drug Manufacturers industry, placing it in the top 69.5%.
Is Elixinol Wellness' Debt-to-Equity too high?
Elixinol Wellness' current Debt-to-Equity of 0.50 is 194% above median its 10-year median of 0.17. The Drug Manufacturers industry median Debt-to-Equity is 0.27. Elixinol Wellness' value of 0.50 is 85.2% above this industry median. Based on the distribution chart, Elixinol Wellness ranks #565 out of 813 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does Elixinol Wellness' Debt-to-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Elixinol Wellness ranks #565 out of 813 companies for Debt-to-Equity. This places Elixinol Wellness in the lower half of its industry. The industry median Debt-to-Equity is 0.27. Elixinol Wellness' value of 0.50 is 85.2% above this benchmark. While the company's 10-year median is 0.17 vs. the industry median of 0.27, Elixinol Wellness has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Elixinol Wellness's current Debt-to-Equity of 0.50 is 85.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Elixinol Wellness and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Elixinol Wellness's current Debt-to-Equity is 0.50, which is 194% above median its own 10-year median of 0.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elixinol Wellness stock overvalued right now?
Based on GuruFocus' analysis, Elixinol Wellness (ASX:EXL) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.02, compared to a current price of A$0.01 — trading 70% below its estimated fair value. The current Debt-to-Equity is 0.50, which is 194% above median its 10-year median of 0.17 and 85.2% above the Drug Manufacturers industry median of 0.27. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Elixinol Wellness (ASX:EXL), the current Debt-to-Equity is 0.50 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Elixinol Wellness Ltd is engaged in the hemp industry, innovating, marketing, and selling hemp-derived nutraceutical, cosmetic, and food products. It operates in the three operating segments of the Americas, Australia, Rest of the World regions of which key revenue is derived from the Australia segment. The Australia segment includes the results from operations of Elixinol Wellness (Byron Bay) Pty Ltd and The Sustainable Nutrition Group Pty Ltd and its subsidiaries. It derives maximum revenue from Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:EXL has been successfully added to your 
